An Aston University researcher has developed a new technique using light which could revolutionize non-invasive medical diagnostics and optical communication.

SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for ...

Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.

The FDA issued an EUA for The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector, now available to qualified healthcare facilities ...

Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S and reimbursed for patients with early ...